{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T04:19:19Z","timestamp":1784089159405,"version":"3.55.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ejphar.2025.178054","type":"journal-article","created":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T06:32:49Z","timestamp":1754721169000},"page":"178054","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Agomelatine and empagliflozin synergistically protect against diabetic cardiomyopathy via nrf2\/HO-1 signaling"],"prefix":"10.1016","volume":"1005","author":[{"given":"Nada A.","family":"Elbaik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimaa M.","family":"Elshazly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atef","family":"El-Gharbawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2437-1773","authenticated-orcid":false,"given":"Mahmoud H.","family":"Elbatreek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2025.178054_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.116019","article-title":"Acetate attenuates cyclophosphamide-induced cardiac injury via inhibition of NF-kB signaling and suppression of caspase 3-dependent apoptosis in wistar rats","volume":"170","author":"Adeyemi","year":"2024","journal-title":"Biomed. pharmacother."},{"key":"10.1016\/j.ejphar.2025.178054_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.fct.2023.114055","article-title":"Cadmium cardiotoxicity is associated with oxidative stress and upregulated TLR-4\/NF-kB pathway in rats; protective role of agomelatine","volume":"180","author":"Alruhaimi","year":"2023","journal-title":"Food Chem. Toxicol. : an int. J. Publish. Br. Ind. Biological Res. Assoc."},{"key":"10.1016\/j.ejphar.2025.178054_bib3","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/01480545.2019.1663209","article-title":"Agomelatine protects heart and aorta against lipopolysaccharide-induced cardiovascular toxicity via inhibition of NF-k\u03b2 phosphorylation","volume":"45","author":"Asci","year":"2022","journal-title":"Drug Chem. Toxicol."},{"key":"10.1016\/j.ejphar.2025.178054_bib4","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.3389\/fphys.2018.01514","article-title":"Diabetic cardiomyopathy: current and future therapies. Beyond glycemic control","volume":"9","author":"Borghetti","year":"2018","journal-title":"Front. Physiol."},{"key":"10.1016\/j.ejphar.2025.178054_bib5","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.2337\/diabetes.51.6.1938","article-title":"Hyperglycemia-induced apoptosis in mouse myocardium: mitochondrial cytochrome c\u2013Mediated Caspase-3 activation pathway","volume":"51","author":"Cai","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2025.178054_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2023.103010","article-title":"Empagliflozin improves mitochondrial dysfunction in diabetic cardiomyopathy by modulating ketone body metabolism and oxidative stress","volume":"69","author":"Cai","year":"2024","journal-title":"Redox Biol."},{"key":"10.1016\/j.ejphar.2025.178054_bib7","doi-asserted-by":"crossref","first-page":"337","DOI":"10.4093\/dmj.2014.38.5.337","article-title":"Diabetic cardiomyopathy and its prevention by nrf2: current status","volume":"38","author":"Chen","year":"2014","journal-title":"Diabetes metabolism J."},{"key":"10.1016\/j.ejphar.2025.178054_bib8","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1152\/physiolgenomics.00041.2017","article-title":"Nrf2 at the heart of oxidative stress and cardiac protection","volume":"50","author":"Chen","year":"2018","journal-title":"Physiol. Genom."},{"key":"10.1016\/j.ejphar.2025.178054_bib9","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000498963","article-title":"The SGLT2 inhibitor empagliflozin might be a new approach for the prevention of acute kidney injury","volume":"44","author":"Chu","year":"2019","journal-title":"Kidney Blood Press. Res."},{"key":"10.1016\/j.ejphar.2025.178054_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/antiox11040784","article-title":"Role of oxidative stress in diabetic cardiomyopathy","volume":"11","author":"De Geest","year":"2022","journal-title":"Antioxidants"},{"key":"10.1016\/j.ejphar.2025.178054_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13185351","article-title":"Prevalence of cardiomyopathy in patients with type 1 diabetes mellitus","volume":"13","author":"Fabila-de la Cruz","year":"2024","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ejphar.2025.178054_bib12","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/3959390","article-title":"The beneficial effects of Chinese herbal monomers on ameliorating diabetic cardiomyopathy via Nrf2 signaling","volume":"2022","author":"Gao","year":"2022","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.ejphar.2025.178054_bib13","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1536\/ihj.18-476","article-title":"Current status and challenges of NRF2 as a potential therapeutic target for diabetic cardiomyopathy","volume":"60","author":"Ge","year":"2019","journal-title":"Int. Heart J."},{"key":"10.1016\/j.ejphar.2025.178054_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11041126","article-title":"Exploring the complex relationship between diabetes and cardiovascular complications: understanding diabetic cardiomyopathy and promising therapies","volume":"11","author":"Ghosh","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejphar.2025.178054_bib15","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12933-023-01917-1","article-title":"Epidemiology of the first-ever cardiovascular event in people with type 1 diabetes: a retrospective cohort population-based study in Catalonia","volume":"22","author":"Gimenez-Perez","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.ejphar.2025.178054_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22115973","article-title":"The mystery of diabetic cardiomyopathy: from early concepts and underlying mechanisms to novel therapeutic possibilities","volume":"22","author":"Grubi\u0107 Rotkvi\u0107","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2025.178054_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2023.110805","article-title":"Type 1 diabetes and risk of heart failure: a systematic review and meta-analysis","volume":"202","author":"Haji","year":"2023","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.ejphar.2025.178054_bib18","doi-asserted-by":"crossref","first-page":"36","DOI":"10.21608\/jram.2024.281277.1241","article-title":"Protective effect of agomelatine on some cardiovascular and metabolic parameters in experimentally induced type 2 diabetes mellitus in rats","volume":"5","author":"Hameed","year":"2024","journal-title":"J. Recent Adv. Med."},{"key":"10.1016\/j.ejphar.2025.178054_bib19","doi-asserted-by":"crossref","first-page":"C331","DOI":"10.1152\/ajpcell.00467.2023","article-title":"RTA 408 ameliorates diabetic cardiomyopathy by activating Nrf2 to regulate mitochondrial fission and fusion and inhibiting NF-\u03baB-mediated inflammation","volume":"326","author":"Hao","year":"2024","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.ejphar.2025.178054_bib20","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.904","article-title":"New insights into the role of melatonin in diabetic cardiomyopathy","volume":"10","author":"Huang","year":"2022","journal-title":"Pharmacol. res. perspectives"},{"key":"10.1016\/j.ejphar.2025.178054_bib21","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/s41420-023-01553-4","article-title":"Diabetic cardiomyopathy: early diagnostic biomarkers, pathogenetic mechanisms, and therapeutic interventions","volume":"9","author":"Huo","year":"2023","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.ejphar.2025.178054_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines8030043","article-title":"Comparative study of the effects of GLP1 analog and SGLT2 inhibitor against diabetic cardiomyopathy in type 2 diabetic rats: possible underlying mechanisms","volume":"8","author":"Hussein","year":"2020","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejphar.2025.178054_bib23","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s11033-025-10260-5","article-title":"Empagliflozin in diabetic cardiomyopathy: elucidating mechanisms, therapeutic potentials, and future directions","volume":"52","author":"Jaiswal","year":"2025","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.ejphar.2025.178054_bib24","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCRESAHA.117.311586","article-title":"Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity","volume":"122","author":"Jia","year":"2018","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejphar.2025.178054_bib25","doi-asserted-by":"crossref","DOI":"10.3892\/mmr.2021.11854","article-title":"Allisartan isoproxil attenuates oxidative stress and inflammation through the SIRT1\/Nrf2\/NF-kappaB signalling pathway in diabetic cardiomyopathy rats","volume":"23","author":"Jin","year":"2021","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.ejphar.2025.178054_bib26","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12933-024-02136-y","article-title":"The double burden: type 1 diabetes and heart failure-a comprehensive review","volume":"23","author":"Julian","year":"2024","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.ejphar.2025.178054_bib27","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1007\/s00210-020-01860-y","article-title":"Role of nitric oxide in mediating the cardioprotective effect of agomelatine against isoproterenol-induced myocardial injury in rats","volume":"393","author":"Khalaf","year":"2020","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.ejphar.2025.178054_bib28","article-title":"FDA expands empagliflozin heart failure indication","volume":"327","author":"Larkin","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.ejphar.2025.178054_bib29","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/216512","article-title":"Prevention of diabetic complications by activation of Nrf2: diabetic cardiomyopathy and nephropathy","volume":"2012","author":"Li","year":"2012","journal-title":"Exp. Diabetes Res."},{"key":"10.1016\/j.ejphar.2025.178054_bib30","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12933-019-0816-2","article-title":"SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart","volume":"18","author":"Li","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.ejphar.2025.178054_bib31","doi-asserted-by":"crossref","first-page":"4775","DOI":"10.2147\/DDDT.S269514","article-title":"SGLT2 inhibitors: a novel player in the treatment and prevention of diabetic cardiomyopathy","volume":"14","author":"Li","year":"2020","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ejphar.2025.178054_bib32","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.4239\/wjd.v14.i12.1862","article-title":"Empagliflozin ameliorates diabetic cardiomyopathy probably via activating AMPK\/PGC-1\u03b1 and inhibiting the RhoA\/ROCK pathway","volume":"14","author":"Li","year":"2023","journal-title":"World J. Diabetes"},{"key":"10.1016\/j.ejphar.2025.178054_bib33","doi-asserted-by":"crossref","first-page":"17657","DOI":"10.1007\/s11356-022-23314-z","article-title":"Protective effect of quercetin against 5-fluorouracil-induced cardiac impairments through activating Nrf2 and inhibiting NF-\u03baB and caspase-3 activities","volume":"30","author":"Lokman","year":"2023","journal-title":"Environ. Sci. Pollut. Res. Int."},{"key":"10.1016\/j.ejphar.2025.178054_bib34","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1111\/jcmm.14870","article-title":"Allopurinol reduces oxidative stress and activates Nrf2\/p62 to attenuate diabetic cardiomyopathy in rats","volume":"24","author":"Luo","year":"2020","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.ejphar.2025.178054_bib35","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1161\/CIRCULATIONAHA.118.034986","article-title":"Incidence of hospitalization for heart failure and case-fatality among 3.25 million people with and without diabetes mellitus","volume":"138","author":"McAllister","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2025.178054_bib36","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2025.178054_bib37","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s10741-018-9749-1","article-title":"Diabetic cardiomyopathy: molecular mechanisms, detrimental effects of conventional treatment, and beneficial effects of natural therapy","volume":"24","author":"Parim","year":"2019","journal-title":"Heart Fail. Rev."},{"key":"10.1016\/j.ejphar.2025.178054_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.907757","article-title":"Signaling pathways related to oxidative stress in diabetic cardiomyopathy","volume":"13","author":"Peng","year":"2022","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.ejphar.2025.178054_bib39","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12933-021-01346-y","article-title":"The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin","volume":"20","author":"Quagliariello","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.ejphar.2025.178054_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.695792","article-title":"The diabetic cardiomyopathy: the contributing pathophysiological mechanisms","volume":"8","author":"Salvatore","year":"2021","journal-title":"Front. Med."},{"key":"10.1016\/j.ejphar.2025.178054_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110260","article-title":"Cardioprotective effects of melatonin: focusing on its roles against diabetic cardiomyopathy","volume":"128","author":"Song","year":"2020","journal-title":"Biomed. pharmacother."},{"key":"10.1016\/j.ejphar.2025.178054_bib42","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22031177","article-title":"Empagliflozin and liraglutide differentially modulate cardiac metabolism in diabetic cardiomyopathy in rats","volume":"22","author":"Trang","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2025.178054_bib43","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","article-title":"Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease","volume":"140","author":"Verma","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2025.178054_bib44","article-title":"Empagliflozin ameliorates diabetic cardiomyopathy via attenuating oxidative stress and improving mitochondrial function","volume":"2022","author":"Wang","year":"2022","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.ejphar.2025.178054_bib45","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.117.028268","article-title":"Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease","volume":"137","author":"Wanner","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2025.178054_bib46","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1042\/BST20150014","article-title":"Dissecting molecular cross-talk between Nrf2 and NF-\u03baB response pathways","volume":"43","author":"Wardyn","year":"2015","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.ejphar.2025.178054_bib47","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202200543RRR","article-title":"Curcumin activates Nrf2\/HO-1 signaling to relieve diabetic cardiomyopathy injury by reducing ROS in vitro and in vivo","volume":"36","author":"Wu","year":"2022","journal-title":"FASEB J."},{"key":"10.1016\/j.ejphar.2025.178054_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107728","article-title":"Synergistic cardioptotection by tilianin and syringin in diabetic cardiomyopathy involves interaction of TLR4\/NF-\u03baB\/NLRP3 and PGC1a\/SIRT3 pathways","volume":"96","author":"Yao","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ejphar.2025.178054_bib49","volume":"vol. 394","author":"Youssef","year":"2021"},{"key":"10.1016\/j.ejphar.2025.178054_bib50","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20112833","article-title":"Contribution of impaired insulin signaling to the pathogenesis of diabetic cardiomyopathy","volume":"20","author":"Zamora","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2025.178054_bib51","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.toxlet.2014.08.017","article-title":"Triptolide-induced oxidative stress involved with Nrf2 contribute to cardiomyocyte apoptosis through mitochondrial dependent pathways","volume":"230","author":"Zhou","year":"2014","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.ejphar.2025.178054_bib52","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925008088?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925008088?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T20:39:58Z","timestamp":1758055198000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299925008088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":52,"alternative-id":["S0014299925008088"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.178054","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Agomelatine and empagliflozin synergistically protect against diabetic cardiomyopathy via nrf2\/HO-1 signaling","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.178054","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"178054"}}